SUMMARY
We performed RNA-Seq and high-resolution mass spectrometry on 128 blood samples from COVID-19 positive and negative patients with diverse disease severities. Over 17,000 transcripts, proteins, metabolites, and lipids were quantified and associated with clinical outcomes in a curated relational database, uniquely enabling systems analysis and cross-ome correlations to molecules and patient prognoses. We mapped 219 molecular features with high significance to COVID-19 status and severity, many involved in complement activation, dysregulated lipid transport, and neutrophil activation. We identified sets of covarying molecules, e.g., protein gelsolin and metabolite citrate or plasmalogens and apolipoproteins, offering pathophysiological insights and therapeutic suggestions. The observed dysregulation of platelet function, blood coagulation, acute phase response, and endotheliopathy further illuminated the unique COVID-19 phenotype. We present a web-based tool (covid-omics.app) enabling interactive exploration of our compendium and illustrate its utility through a comparative analysis with published data and a machine learning approach for prediction of COVID-19 severity.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported in part by the National Institutes of Health. Specifically, by the National Human Genome Research Institution through a training grant to the Genomic Sciences Training Program Grant 5T32HG002760 (T.M.P.), the National Heart, Lung, and Blood Institute (NHLBI) through awards K01-HL-130704 (A. Jaitovitch) and 5R01HL-049426 (H. A. Singer) and by the National Institute of General Medical Sciences through 1R01GM124133 (A. P. Adam) and The National Center for Quantitative Biology of Complex Systems (5P41GM108538, J.J. Coon). Further support was provided by the Collins Family Foundation Endowment (A. Jaitovitch), and the Morgridge Institute through a postdoctoral fellowship (M.N.B.).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was obtained from the Albany Medical College Committee on Research Involving Human Subjects (IRB# 5670-20).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Mass spectrometry raw files and the SQLite database file have been deposited to the MassIVE database (accession number MSV000085703). Raw fastq data and RSEM expression estimates are available at GEO accession XXXXXX (note, data have been submitted and we are waiting for an accession number assignment). RSEM expression estimates for Englert samples can be downloaded from the MassIVE database.
https://massive.ucsd.edu/ProteoSAFe/dataset.jsp?accession=MSV000085703
